Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
MD Faruque Pathan, Nazma Akter, Shahjada Selim, M Saifuddin, Nazmul Kabir Qureshi, ABM Kamrul-Hasan, Mohammad Abdul Hannan, Md Ashraf Uddin Ahmed, Marufa Mustari & Ashish Kumar Chakraborty. (2022) Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh. Diabetes, Metabolic Syndrome and Obesity 15, pages 4011-4021.
Read now
Read now
Sanjay Kalra, Das A. K.Fariduddin Md.Shaikh K.Shah P.Rehim A. A.John M.Shaikh S.Orabi A.Saraswati M. R.Shahjada Selim, Baruah M. P.K. K. Gangopadhyay, Langi Y. A.Nair T.Dhanwal D.Thapa S. D.Deshmukh V.D. Dutta, Khalfan H.Maskey R.Das S.Dasgupta A.Bajaj A.Priya G.Chandrasekaran S.A. Dhingra, Pandey N, Al Ani A.Moosa M.. (2021) Glucodynamics and glucocracy in type 2 diabetes mellitus: clinical evidence and practice-based opinion on modern sulfonylurea use, from an International Expert Group (South Asia, Middle East & Africa) via modified Delphi method. Current Medical Research and Opinion 37:3, pages 403-409.
Read now
Read now
Nesreen Aldawi, Gassan Darwiche, Salah Abusnana, Murtada Elbagir & Targ Elgzyri. (2019) Initial increase in glucose variability during Ramadan fasting in non-insulin-treated patients with diabetes type 2 using continuous glucose monitoring. Libyan Journal of Medicine 14:1.
Read now
Read now
Salah Shelbaya & Sameh Rakha. (2017) Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Current Medical Research and Opinion 33:5, pages 797-801.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2016) Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Review of Clinical Pharmacology 9:6, pages 839-851.
Read now
Read now
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
Kamran MA Aziz. (2015) Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes, Metabolic Syndrome and Obesity 8, pages 207-211.
Read now
Read now
Articles from other publishers (10)
GR Sridhar, Kaushik Pandit, Sona Warrier & Ashish Birla. (2023) Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review. Cureus.
Crossref
Crossref
Mahmoud Ibrahim, Mary Moffett Barker, Ehtasham Ahmad, Asma Ahmed, Firas A. Annabi, Ebtesam M. Ba‐Essa, Melanie J. Davies, Pamela Houeiss, Hinde Iraqi, Shabeen Naz Masood, Safia Mimouni‐Zerguini, Shehla Shaikh, Hyam Tantawi & Jaakko Tuomilehto. (2023) Optimizing Ramadan fasting: A randomised controlled trial for people with type 2 diabetes during Ramadan applying the principles of the ADA/EASD consensus. Diabetes/Metabolism Research and Reviews 39:3.
Crossref
Crossref
Viswanathan Mohan, Subhash Wangnoo, Sambit Das, Rajnish Dhediya & Kumar Gaurav. (2022)
Comparison of gliclazide
vs
linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
. World Journal of Diabetes 13:12, pages 1168-1183.
Crossref
Crossref
Sumera Ahmed, Natasha Khokhar & Jay H. Shubrook. (2022) Fasting during Ramadan: A Comprehensive Review for Primary Care Providers. Diabetology 3:2, pages 276-291.
Crossref
Crossref
Rashmi Shiju, Ayesha Akhil, Smitha Thankachan, Jaakko Tuomilehto, Monira Al Arouj & Abdullah Bennakhi. (2022) Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022, pages 1-11.
Crossref
Crossref
Dana Abdelrahim, MoezAlIslam E. Faris, Mohamed Hassanein, Ayman Z. Shakir, Ayesha M. Yusuf, Aljohara S. Almeneessier & Ahmed S. BaHammam. (2021) Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Frontiers in Endocrinology 12.
Crossref
Crossref
Huai Heng Loh & Nor Azmi Kamaruddin. (2020) Treatment Options for Patients with Type 2 Diabetes Mellitus during the Fasting Month of Ramadan. Annals of the Academy of Medicine, Singapore 49:7, pages 468-476.
Crossref
Crossref
Mussa H. Almalki & Fahad Alshahrani. (2016) Options for Controlling Type 2 Diabetes during Ramadan. Frontiers in Endocrinology 7.
Crossref
Crossref
Ehab Mudher Mikhael. (2016) Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research 2016, pages 1-10.
Crossref
Crossref
Gábor Winkler. (2015)
Sulfonylureas in today’s blood glucose lowering therapy.
New data on advantages and potential barriers of an “old” antidiabetic group
. Orvosi Hetilap 156:13, pages 511-515.
Crossref
Crossref